Hanyu Pharmaceutical (300199.SZ): HY3003 injection has completed pre-clinical animal pharmacodynamics studies

Zhitong Finance App News, Hanyu Pharmaceutical (300199.SZ) issued an announcement. Recently, the company obtained the “Summary Report on the Pharmacodynamics of HY3003 Injection Subcutaneously Administered to DIO Mice” and the “Summary Report on Pharmacodynamics Tests of HY3003 Injection Administered Subcutaneously to DIO Mice”. The report shows that the new-generation GLP-1/GIP/GCGR triple agonist HY3003 injection developed by the company has completed pre-clinical animal pharmacodynamics studies.

The results of this preclinical pharmacodynamics study have verified the differentiated efficacy advantages of HY3003 in the field of three-target metabolic drugs. The HY3003 long-acting sustained-release formulation uses a storage sustained-release mechanism to maintain stable drug concentrations in the body, reduce gastrointestinal adverse reactions caused by peak blood drug concentrations, and is expected to improve patients' adherence to medication. The smooth progress of the project will help enhance the company's innovative capabilities and product diversity in the field of metabolic disease treatment.